Introducing A New Normal for Clinical Trials
In early March 2020, when the first wave of COVID-19 rolled into the continental U.S., leaders from every industry were forced to abandon business as usual and embrace new strategies and operational practices. For some, these adjustments are stopgaps that will be dismissed when the pandemic subsides. For others, like Leading BioSciences, Inc. (LBS) – now known as Palisade Bio – an emergency pivot to a Donnelley Financial Solutions (DFIN) tool turned out to be a process game changer now here to stay.